Articles tagged "Rejection"

2017 American Transplant Congress
Kidney-Specific Immunosuppression without Adverse Systemic Effects.
D. Kentrup,¹ K. Schuette-Nuetgen,¹ H. Pawelski,¹ H. Pavenstädt,¹ S. Hermann,² M. Schaefers,² G. Larbig,³ A. Kuebelbeck,³ S. Reuter.¹
¹Department of Medicine D, University Hospital Muenster, Muenster, Germany; ²European Institute for Molecular Imaging - EIMI, University Hospital Muenster, Muenster, Germany; ³Merck KGaA, Darmstadt, Germany
Purpose: Immunosuppressive therapy is often accompanied by severe adverse effects. To overcome this, the aim of this study was the evaluation of a kidney-specific drug…
2017 American Transplant Congress
HLA Class II Molecules Partner with TLR4 to Stimulate Endothelial Cell Activation and Proliferation.
Y.-P. Jin, E. Reed.
Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, CA
Background: Transplant recipients developing donor specific HLA antibodies (DSA) are at a higher risk for acute and chronic antibody-mediated rejection (AMR). DSA contribute to the…
2017 American Transplant Congress
Bortezomib for Late Antibody-Mediated Rejection After Renal Transplantation: A Single Center Experience of 22 Cases.
J. Choi, J. Jung, S. Chun, S. Shin, Y. Kim, D. Han.
Department of General Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
Despite of tradifional treatments for AMR, such as plasapheresis, ingravenous immunoglobulin, and rituximab, current treatment for antibody-mediated rejection(AMR) after renal transplantation is insufficient. Recently, Bortezomib…
2017 American Transplant Congress
Distinctive Molecular Features of Antibody-Mediated versus T-Cell Mediated Rejection in Facial Transplantation.
R. Lopdrup, T. Win, N. Murakami, J. Teague, A. Chandraker, G. Murphy, C. Lian, E. Bueno, B. Pomahac, R. Clark, L. Riella.
Brigham and Women's Hospital, Boston, MA
BackgroundA single case of antibody-mediated rejection in a clinical face transplant has been reported worldwide. The availability of repeated allograft biopsies from this patient allowed…
2017 American Transplant Congress
Do Perioperative Blood Transfusions Influence Kidney Transplant Outcomes in the Modern Era?
J. Lineen, J. Trac, Y. Li, O. Famure, J. Kim.
Multi-Organ Transplant Program, Toronto General Hospital, University Health Network, Toronto, ON, Canada
Background: Blood transfusions are a well-established risk factor for human leukocyte antigen sensitization in kidney transplant candidates. To date, relatively few studies have explored the…
2017 American Transplant Congress
Rejection of Human Kidney Allografts According to BANFF Classification Is Associated with a Chemokine-Enriched Protein Microenvironment in Biopsy Tssue.
C. Falk,¹ K. Daemen,¹ J. Keil,¹ F. Lehner,² H. Haller,³ J. Schmitz,⁴ J.-H. Bräsen,⁴ C. Blume.⁵
¹Institute of Transplant Immunology, IFB-Tx, Hannover Medical School, Hannover, Germany; ²Department of Abdominal, Visceral and Transplantation Surgery, Hannover Medical School, Hannover, Germany; ³Department of Nephrology and Hypertension, Hannover Medical School, Hannover, Germany; ⁴Institute of Pathology, Hannover Medical School, Hannover, Germany; ⁵Institute for Technical Chemistry, Leibniz University, Hannover, Germany
Background: Expression profiling efforts of biopsy tissue after kidney transplantation indicate that rejection can be defined by distinct signatures. Based on pathological evaluation (BANFF) as…
2017 American Transplant Congress
Prediction of Renal Allograft Acute Rejection Using a Novel Non-Invasive Model Based on Acoustic Radiation Force Impulse.
C. Yang,¹ Y. Jin,² S. Wu,³ T. Zhu,¹ W. He.²
¹Urology, Zhongshan Hospital, Fudan University, Shanghai, China; ²Ultrasound, Zhongshan Hospital, Fudan University, Shanghai, China; ³Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University, Shanghai, China
Point shear wave elastography (p-SWE) based on acoustic radiation force impulse (ARFI) is a novel technology to quantify tissue stiffness by measuring shear wave speed…
2017 American Transplant Congress
Adjunctive Thymoglobulin with Proteasome Inhibitor Based Treatment of Late Mixed Acute Rejection.
A. Lichvar,¹ A. Leino,¹ S. Tremblay,¹ A. Shields,² F. Paterno,¹ A. Govil,¹ M. Anand,¹ T. Diwan,¹ J. Kremer,² R. Alloway,¹ E. Woodle.¹
¹University of Cincinnati, Cincinnati; ²The Christ Hospital, Cincinnati
Proteasome inhibitor (PI) containing regimens treat mixed acute rejection (MAR) at least in part due to elimination of donor specific antibody (DSA) and via effects…
2017 American Transplant Congress
mTOR Inhibition Diminishes Peripheral Blood CD8⁺CD28^–CD38^hi Effector/Memory T Cells and Facilitates Resolution of Belatacept-Refractory Kidney Rejection.
C. Castro-Rojas,¹ A. Godarova,¹ A. Leino,² R. Alloway,² M. Jordan,³ E. Woodle,² D. Hildeman.¹
¹Division of Immunobiology, Cincinnati Children's Hospital, University of Cincinnati College of Medicine, Cincinnati, OH; ²Division of Transplantation, University of Cincinnati College of Medicine, Cincinnati, OH; ³Division of Bone Marrow Transplant and Immune Deficiency, Cincinnati Children's Research Foundation, Cincinnati, OH
Belatacept, a CD28-CD80/86 blocker, was approved by the FDA to provide immunosuppression without nephrotoxicity or cardiovascular and metabolic adverse effects. As part of our multi-center…
2017 American Transplant Congress
Organs with Extended Cold Ischemia Time May Offer Aged Kidney Transplant Recipients New Options in an Expanded Donor Pool.
M. Postalcioglu,¹ B. Byun,¹ A. Kaze,² A. Siedlecki,¹ E. Milford,² R. Abdi.¹
¹Transplantation Research Center, Brigham and Women's Hospital, Boston, MA; ²Renal Division, Brigham and Women's Hospital, Boston, MA
Using data from the largest cohort of renal transplants, the aim of this study was to examine the effects of cold ischemia times (CIT) on…